Bromocriptine and Insulin Sensitivity

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

In this study the investigators will examine the effect of dopamine (bromocriptine) on insulin sensitivity in lean and obese subjects. Furthermore, the investigators will examine whether the timing of bromocriptine administration has influence on insulin sensitivity.

To do so, the investigators will include lean and obese subjects who will use 2 times 2 weeks bromocriptine. In randomized order, they will use it in the morning or in the evening.

The investigators will examine insulin sensitivity by performing a 7-point oral glucose tolerance test.

Furthermore, the investigators will examine energy expenditure and subjects will keep track of their eating behaviour in the 3 days before each study visit.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
• Treatments: Bromocriptine; Insulin

Criteria

Inclusion Criteria:

• Caucasian origin

• Subjects should be able and willing to give informed consent

• BMI range of 19-23 kg/m2 or BMI> 27 kg/2

Exclusion Criteria:

• Renal failure (creatinine>135mmol/l)

• Liver failure (ASAT/ALAT > 3 times higher than the normal upper value)

• Daily use of prescription medication

• Known hypersensitivity to bromocriptine.

• Uncontrolled hypertension

• Known history of coronary artery disease or valvulopathy

• History of severe psychiatric disorders.

• Prolactin-releasing pituitary tumor (prolactinoma).